XTL Biopharmaceuticals Ltd
XTLB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001023549
No open-market purchases or sales by XTL Biopharmaceuticals Ltd insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $20.7K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding XTL Biopharmaceuticals Ltd changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 5 | 4 | −1 |
| Shares | 258.9K | 253.1K | −5.89K (−2.3%) |
| Value | $727.8K | $613.4K | −$114.4K (−15.7%) |
New holders (1)
Institutions that held XTL Biopharmaceuticals Ltd at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Rhumbline Advisers | 5,584 | $13.2K | 0.00% |
Sold out (2)
Institutions that held XTL Biopharmaceuticals Ltd at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| UBS Group AG | 6,954 | $19.5K |
| BNP Paribas Arbitrage, SA | 300 | $843 |